Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly

Chad M. VanDenBerg, Yusuf Kazmi, Michael W. Jann

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


The treatment of Alzheimer's disease is of increasing importance as the population ages and the number of people with the disease increases. The aetiology of Alzheimer's disease is complex and therefore treatment strategies rely on generalised pathological findings. Cholinesterase inhibitors enhance a generalised deficit of central nervous system acetylcholine and are the first class of agents specifically approved for the treatment of Alzheimer's disease. The clinical efficacy of the different cholinesterase inhibitors is similar; however, differences in pharmacodynamic and pharmacokinetic parameters can influence tolerability and safety in the elderly population. Concomitant disease states, significant drug interactions and the altered kinetics and dynamics seen in elderly patients can also affect treatment outcome. Although cholinesterase inhibitors are not 'curative' for Alzheimer's disease, clinical evidence indicates that these drugs can significantly delay the progress of cognitive impairment. Consequently, they represent a useful treatment for the symptoms of Alzheimer's disease in the elderly.

Original languageEnglish
Pages (from-to)123-138
Number of pages16
JournalDrugs and Aging
Issue number2
StatePublished - 2000


Dive into the research topics of 'Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly'. Together they form a unique fingerprint.

Cite this